drugset / Trial / NCT00705692

Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients

NCT00705692

Phase 2 Completed 40 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Levamisole as an immunomodulator drug has been demonstrated to improve the immune response to Hepatitis B virus (HBV) vaccination in hemodialysis patients. The aim of this study was to evaluate the effect of levamisole supplementation on tetanus-diphtheria (Td) vaccine response rate in hemodialysis patients.

Timeline

Start
2008-03
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levamisole Small molecule 100 mg

Indications

No indication recorded.